⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256987 | 0.73 | — | — | |
| SCHEMBL17734082 | 0.65 | — | — | |
| SCHEMBL16801438 | 0.65 | — | — | |
| SCHEMBL14178735 | 0.61 | — | — | |
| SCHEMBL10296615 | 0.61 | — | — | |
| SCHEMBL158226 | 0.61 | — | — | |
| SCHEMBL7589478 | 0.60 | — | — | |
| Bromide SCHEMBL28296934 | 0.59 | — | — | |
| SCHEMBL249133 | 0.58 | — | — | |
| SCHEMBL13228788 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| EP-4234549-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234553-A2 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-2888241-B1 | 2,4,5,6-Substituted 3,6-dihydropyrimidine derivatives as hepatitis B virus (HBV) polymerase inhibitors for the treatment of e.g. chronic hepatitis | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-07-12 | — | — | EP | disclosed |
| US-9630928-B2 | Intermediates to prepare herbicidal pyrimidone derivatives | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2890698-B1 | DIOXINO- AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| WO-2016057572-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MILLER MARK THOMAS (US) | 2016-04-14 | — | — | WO | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2344475-B1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8546420-B2 | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2013092516-A1 | USE OF AN ANTHRANILIC DIAMIDE DERIVATIVES WITH HETEROAROMATIC AND HETEROCYCLIC SUBSTITUENTS IN COMBINATION WITH A BIOLOGICAL CONTROL AGENT | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7662823-B2 | Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090075916-A1 | Use of Macrolide Derivatives for Treating Acne | RANBAXY LABORATORIES LIMITED (IN) | 2009-03-19 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |